Categories
Mankind Pharma Limited — Updates, 19-05-2026: Press Release
19-05-2026 · 08:07 pm
Mankind Pharma's Q4 FY26 revenue grew 11.8% to ₹3,443 Cr, with PAT soaring 30.4%. Domestic sales rose 13.4%, powered by chronic therapies like cardiac and anti-diabetes, plus strong OTC growth. International business was muted.
No comments yet. Be the first to comment!